RINVOQ

Abbvie Corporation🇨🇦 Health Canada

Approval Id: 3c5cdcdf00adba6a
Drug Approval Canada Name: RINVOQ
Product Name: RINVOQ
Status: Marketed
Status Date: 2023-09-07
Original Market Date: 2023-09-07
Din: 02539721
Drug Class: Human
Dosage Form: Tablet (Extended-Release)
Route Of Administration: Oral
Schedule: Prescription
Ahfs: 90:24.12.92
Atc Original: L04AF03 UPADACITINIB
Atc Name: l 04 af 03
Aig Number: 0162012003
Company Name: Abbvie Corporation
Company Address: 8401 Trans-Canada Highway, Saint-Laurent, Quebec, Canada, H4S 1Z1
Company Detail Path: /organization/abbvie-corporation

UPADACITINIB

45 MG

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

3c5cdcdf00adba6a

Type

Standard